Related references
Note: Only part of the references are listed.Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
Elizabeth C. Hsia et al.
ARTHRITIS AND RHEUMATISM (2012)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
D. E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treatment of latent tuberculosis infection: An update
Philip Lobue et al.
RESPIROLOGY (2010)
Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFα
Ismail Hanta et al.
CLINICAL RHEUMATOLOGY (2007)
Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection
Juan J. Gomez-Reino et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
L Carmona et al.
ARTHRITIS AND RHEUMATISM (2005)
Share Paper
